Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire ...
Just over a year ago, researchers reported that they had isolated and characterized a long-sought second form of acetylsalicylic acid, known in most households as aspirin (J. Am. Chem. Soc. 2005, 127, ...
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent pending drug delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback